Investors & Media


HomeInvestors & MediaNews

ABL Bio to Present ABL602 Data at the 63rd ASH Annual Meeting

- ABL602 is a CLL-1/CD3 bispecific antibody for acute myeloid leukemia

- Preclinical data highlight potential of ABL602 as a new treatment for AML


November 5, 2021, SEONGNAM - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced that new preclinical data for its ABL602, a T-cell engager bispecific antibody targeting CLL-1 and CD3 to treat acute myeloid leukemia (AML), will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place both online and offline from December 11-14, 2021.


“As part of our aim to apply our innovative bispecific antibody technology to a wide range of indications, we are striving to expand our portfolio of blood cancer therapeutics,” said Sang Hoon Lee, PhD, CEO of ABL Bio. “We look forward to participating in the 2021 ASH annual meeting, which will be the first time we showcase ABL602 to a global audience.”


Details of the accepted abstract are as follows:


Title: A Novel Asymmetrical Anti-CLL-1 x CD3 Bispecific Antibody, ABL602, Induces Potent CLL1-Specific Antitumor Activity with Minimized Sensitization of Pro-Inflammatory Cytokines

Abstract Number: 145274

Session Title: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Date & Time: 6:00 PM – 8:00 PM, Sunday, December 12, 2021


About ABL Bio

ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit


ABL Contacts

Investor Inquiries

Hyunjun Kim

+82 31 8018 9845

Media Inquiries

Hee Jun Park

+82 31 8014 7032





[Korea Times] ABL Bio leading Korea's new drug development
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson’s Disease